

**Supplementary Table 1.** Summary statistics for residual effects parameters (all-participants-treated population; observed case)

Statistic	Change from baseline to end of treatment	
	Esmirtazapine 1.5 mg (n=128)	Esmirtazapine 3.0 mg (n=131)
Alertness at awakening		
n	123	128
Median (range)	17 (-71 to 97)	15 (-46 to 88)
Mean (SD)	18.3 (29.2)	16.2 (24.9)
p-value	<0.0001	<0.0001
Feeling full of energy the past 7 days		
n	123	128
Median (range)	13 (-87 to 95)	11 (-58 to 83)
Mean (SD)	16.1 (27.7)	13.6 (24.3)
p-value	<0.0001	<0.0001
VAS rating on ability to work/function		
n	123	128
Median (range)	12 (-77 to 94)	12 (-50 to 88)
Mean (SD)	14.7 (26.7)	14.6 (23.1)
p-value	<0.0001	<0.0001
Total nap time (min)		
n	25	25
Median (range)	-1 (-45.0 to 40.0)	5 (-120.0 to 30.0)
Mean (SD)	-2.8 (16.7)	-0.9 (27.4)
p-value	0.4174	0.8737

SD: standard deviation, VAS: visual analog scale